{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:36:49Z","timestamp":1786649809289,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.172126","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:02:32Z","timestamp":1767790952000},"page":"961-963","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity associated with bortezomib: A single-center experience"],"prefix":"10.4103","volume":"13","author":[{"given":"Murali Krishna","family":"Gurram","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, HealthEast Care System, St. Paul, Minnesota, 55102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroopa","family":"Pulivarthi","sequence":"additional","affiliation":[{"name":"Department of Research, HealthEast Care System, St. Paul, Minnesota, 55102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Ehresmann","sequence":"additional","affiliation":[{"name":"Department of Data Science, HealthEast Care System, St. Paul, Minnesota, 55102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josy","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Oncology, HealthEast Care System, St. Paul, Minnesota, 55102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R3-20260109","first-page":"171","article-title":"The ubiquitin-proteasome system as a molecular target in solid tumors: An update on bortezomib","volume":"2","author":"Milano","year":"2009","journal-title":"Onco Targets Ther"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2459\/JCM.0b013e32832f3ff2","article-title":"Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance","volume":"11","author":"Foley","year":"2010","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1078155210367839","article-title":"Complete heart block secondary to bortezomib use in multiple myeloma","volume":"17","author":"Dasanu","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: A case report and review of the literature","volume":"128","author":"Bockorny","year":"2012","journal-title":"Acta Haematol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12012-011-9146-7","article-title":"Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma","volume":"12","author":"Gupta","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","article-title":"Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma","volume":"91","author":"Takamatsu","year":"2010","journal-title":"Int J Hematol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2407-6-129","article-title":"Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report","volume":"6","author":"Voortman","year":"2006","journal-title":"BMC Cancer"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Enrico","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201713060-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:39Z","timestamp":1786647519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201713060-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.172126","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}